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Background: The aim of this study was to compare the effect of anemia on clinical outcomes according to age in 
patients with end-stage renal disease (ESRD).
Methods: A total of 3,409 patients from the Clinical Research Center for ESRD were included and divided into three 
groups by age: age < 40 (n = 488), 40 ≤ age < 60 (n = 1,650), and age ≥ 60 (n = 1,271). We compared overall 
and cardiovascular mortality, and all-cause and cardiovascular hospitalization according to mean hemoglobin (Hb) 
concentration.
Results: Among participants ≥ 60 years of age, the Hb < 10 g/dL group had greater all-cause mortality (adjusted 
hazard ratio [HR], 2.098; 95% confidence interval [CI], 1.567-2.808; P < 0.001) than the 10 ≤ Hb < 12 g/dL group, 
whereas among participants < 40 years of age, the Hb ≥ 12 g/dL group had greater mortality than the 10 ≤ Hb < 12 g/dL 
group. Moreover, in participants ≥ 60 years of age, the HR for all-cause hospitalization for the Hb < 10 g/dL group was 
significantly greater than that of the 10 ≤ Hb < 12 g/dL group (HR, 1.472; 95% CI, 1.057-2.051; P = 0.022), whereas 
it was significantly lower in the Hb ≥ 12 g/dL group (HR, 0.544; 95% CI, 0.362-0.820; P = 0.004) However, among 
participants < 40 years of age, the incidence of all-cause hospitalization did not differ according to the Hb concentration 
(HR, 1.273; 95% CI, 0.814-1.991; P = 0.290 for the Hb < 10 g/dL group; reference, 10 ≤ Hb < 12 g/dL; HR, 0.787; 
95% CI, 0.439-1.410; P = 0.265 for Hb ≥ 12 g/dL group).
Conclusion: The impact of anemia on mortality was more significant in elderly ESRD patients. Strict monitoring and 
management of anemia should be required for elderly ESRD patients.
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Introduction
Anemia is an important complication of end-stage renal 
disease (ESRD), and treatment of anemia is correlated 
with an improvement in the patient’s quality of life, and 
with a reduction in morbidity and mortality [1-3]. There-
fore, it is strongly recommended to use erythropoiesis-
stimulating agents (ESAs) and iron therapy, which are 
considered beneficial for the correction of anemia, in pa-
tients with ESRD [4,5]. However, the results of some stud-
ies have suggested potential harm due to overtreatment 
of anemia when employing ESAs, defined as achieving 
a hemoglobin (Hb) concentration of 12 g/dL and above, 
which may potentially lead to increased cardiovascular 
events and mortality [6,7]. The Kidney Disease Improving 
Global Outcomes (KDIGO) guidelines therefore currently 
recommend maintaining Hb concentrations between 10 
to 12 g/dL in clinical practice [4].
Despite these recommendations, a previous report 
suggested that the optimal Hb concentration may vary 
according to the patient’s age [7]. This report found that 
in children on hemodialysis (HD), Hb concentrations 
of 12 g/dL and above are not associated with increased 
incidences of cardiovascular visits, mortality, or all-
cause and cardiovascular disease (CVD)-related hospi-
talizations, in contrast to the reported harmful impact of 
overcorrected Hb in adult ESRD patients. Another study 
reported that anemia resulted in a more significant im-
pact in elderly ESRD patients than in younger patients 
with respect to CVD and ESRD-related mortality of that 
population demographic [6,7]. These studies suggest that 
anemia and/or overcorrected Hb are associated with dif-
ferential impacts on patient outcomes according to the 
patient’s age. 
Based on above findings, the aim of this study was to 
investigate whether anemia is associated with differential 
impacts on clinical outcomes according to age group us-
ing a well-established nation-wide ESRD cohort within 
Clinical Research Center for ESRD (CRC-ESRD). 
Methods
Study population 
We analyzed the CRC-ESRD data. The CRC-ESRD da-
tabase contained a total of 5,244 cases from 31 centers in 
Korea. The cohort was established in April 2009, and in-
cluded adult (> 18 years of age) dialysis patients. For the 
present study, we excluded patients whose age data was 
not available, or whose Hb concentrations had not been 
measured at least three times during the study period; a 
total of 1,835 patients were excluded, and 3,409 patients 
were included in the final analyses (Fig. 1).
A total of 2,058 patients on HD, 1,332 patients on peri-
toneal dialysis (PD), 7 patients with changes in treatment 
modality (HD → PD or PD → HD), and 12 patients with 
missing data regarding treatment modality were enrolled 
in this cohort. Additionally, 1,157 incident and 2,252 
prevalent dialysis patients were included in the analyses. 
The CRC registry for ESRD was approved by the medi-
cal ethics committees of all participating hospitals, and 
informed consent was obtained from all patients before 
inclusion. All participants were assigned to one of three 
groups (age < 40, 40 ≤ age < 60, or age ≥ 60 years) accord-
ing to their age at enrollment of this study for maintained 
HD patients, or according to their age at the initiation of 
dialysis for incidental dialysis patients. 
Data collection 
This was a prospective cohort study of dialysis patients 
in Korea receiving HD for ESRD during the years 2009 
to 2015. The baseline demographic and clinical data, 
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Figure 1. Distribution of patient population according to patient 
age. Of the 5,244 subjects included in the Clinical Research Center 
for end-stage renal disease (CRC-ESRD) registry, 1,835 subjects 
were excluded due to lack of information regarding age or hemoglo-
bin (Hb) concentration. Therefore, 3,409 patients were included: 
488 were younger than 40 years of age, 1,650 were between 40 
and 60 years of age, and 1,271 were 60 years of age or older. 
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including age, sex, and laboratory investigations, were 
recorded for all patient participants. For the assessment 
of mean Hb concentration, we calculated the average 
of every serum Hb measurement during the follow-up 
period. The patients were divided into 3 groups accord-
ing to their mean Hb concentration as Hb < 10 g/dL, 10 ≤ 
Hb < 12 g/dL, and Hb ≥ 12 g/dL [7]. We also categorized 
patients according to age as < 40 years, 40 ≤ age < 60 years, 
and age ≥ 60 years [8]. 
Baseline demographic and clinical data including age, 
gender, height, weight, co-morbidities, laboratory inves-
tigations, and therapeutic characteristics were recorded. 
Additionally, serum Hb, albumin, ferritin, transferrin 
saturation (TSAT) concentrations were determined from 
the patients’ blood samples. The single-pool Kt/V (spKt/
V) was determined using two-point urea modelling based 
on the intradialytic reduction in blood urea and intradia-
lytic weight loss. For assessment of co-morbidities, modi-
fied Charlson comorbidity scores were used. 
Outcomes
The primary outcome of this study was a review of all-
cause mortality. For each death, the principal investiga-
tor at the given institution completed a form recording 
the cause of death according to the CRC registry for ESRD 
study classification. The median follow-up duration was 
24.4 months (3 to 81 months), and the dates and causes 
of mortality were immediately reported throughout the 
follow-up period. Additionally, the secondary outcomes 
of this study were CVD-related mortality, all-cause hos-
pitalization, and CVD-related hospitalization. A report 
of CVD-related mortality or hospitalization referred to 
death or admission due to a cardiovascular event, such as 
heart failure, arrhythmia, ischemic cardiovascular event, 
or stroke. 
Statistical analyses
The patient characteristics were examined using de-
scriptive statistics for continuous variables (mean, me-
dian) and categorical variables (number [%]), and the 
results were stratified by patient Hb concentration at 
baseline. A χ2 tests for independence was used to test for 
differences by Hb group. Similarly, we summarized the 
outcomes (death, hospitalizations, and cardiac events) 
Table 1. Comparison of the baseline characteristics of the study population according to patient age 
Characteristic Age < 40 years 40 ≤ age < 60 years Age ≥ 60 years P value
No. of patients 488 (14.3) 1,650 (48.4) 1,271 (37.3)
Mean age of patients (yr) 33.6 51.6 68.8 < 0.001
Male sex 268 (54.9) 915 (55.5) 761 (59.9) 0.064
Cause of ESRD < 0.001
   DM 100 (20.5) 687 (41.6) 627 (49.3)
   GN 158 (32.4) 251 (15.2) 104 (8.2)
   Renal vascular disease 4 (0.8) 0 (0) 2 (0.2)
   Other 226 (46.3) 712 (43.2) 538 (42.3)
Duration of dialysis (mo) 24.6 29.3 28.0 0.106
Incidental dialysis 195 (40.0) 531 (32.2) 431 (33.9) 0.006
Mean Hb concentration (g/dL) < 0.001
   Hb < 10 148 (30.3) 436 (26.4) 274 (21.6)
   10 ≤ Hb < 12 274 (56.1) 1,068 (64.7) 874 (68.8)
   Hb ≥ 12 66 (13.5) 146 (8.8) 123 (9.7)
Mean albumin (g/dL) 3.5 3.4 3.5 0.337
Mean ferritin (ng/mL) 245 279 308 0.126
Mean TSAT (%) 33.1 32.0 32.5 0.136
Mean iPTH (pg/mL) 664.6 662.4 634.0 0.663
Mean CRP (mg/L) 3.24 2.30 2.62 0.160
Data are presented as number (%) or number only.
CRP, C-reactive protein; DM, diabetes mellitus; ESRD, end-stage renal disease; Hb, hemoglobin; iPTH, intact parathyroid hormone; GN, glomerulonephritis; TSAT, 
transferrin saturation. 
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with descriptive statistics (number [%]). Broadly speak-
ing, the confidence intervals (CIs) were estimated using a 
normal approximation of the Poisson distribution. Last, 
we estimated the adjusted HR of mortality using a Cox 
proportional hazards model. In this case, the models 
were adjusted for all patient demographic and clinical 
characteristics studied, such as gender, primary renal 
disease, duration of dialysis, modified Charlson comor-
bidity index, and mean intact parathyroid hormone level 
(iPTH). All results were stratified by mean Hb groups 
with Hb concentrations with 10 to < 12 g/dL as the refer-
ence, P values less than 0.05 were considered statistically 
significant. All analyses were conducting using IBM SPSS 
Statistics for Windows ver. 21.0 (IBM Corp., Armonk, NY, 




Among the study population, 14.3% (n = 488) were < 40 
years of age, 48.4% (n = 1,650) were 40 ≤ age < 60 years of 
age, and 37.3% (n = 1,271) were ≥ 60 years of age. Table 
1 presents the baseline characteristics among differ-
ent groups according to the patient’s age. Generally, the 
gender distribution was not different within groups. The 
cause of ESRD was different according to the patients’ 
ages, and diabetes mellitus (DM) was the most com-
mon cause of ESRD in the age ≥ 60 years group (49.3%). 
In contrast, glomerulonephritis was the most common 
cause of ERSD in both of the younger age groups (age < 40 
years and 40 ≤ age < 60 groups; P < 0.001 for each). There 
were no differences between the mean durations of dialy-
sis in all the groups (P = 0.106), which were 24.6 months 
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Figure 2. Comparison of patient survival according to patient age. (A) Survival according to hemoglobin (Hb) concentration in the overall 
population and in patients (B), under 40 years of age, (C) between 40 to 60 years of age, and (D) over 60 years of age. 
*P < 0.05 vs. Hb < 10, †P < 0.05 vs. 10 ≤ Hb < 12.
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(± 1.8) in the age < 40 group, 29.3 (± 1.1) months in the 
40 ≤ age < 60 group, and 28.0 (± 1.2) months in the age ≥ 
60 months group. Mean serum albumin concentrations, 
which generally reflect the nutritional status of dialysis 
patients, did not differ among the three age groups (P = 
0.337). Other anemia profiles, such as mean serum fer-
ritin and TSAT concentrations also did not differ between 
the groups (P = 0.126, P = 0.136 for each).
Overall patient survival 
A total of 363 deaths were reported among the over-
all study population during the follow-up period (24.4 
months; range, 3-81 months). In the overall patient pop-
ulation, the patient survival rate was greatest in the 10 ≤ 
Hb < 12 g/dL group, but there was no difference between 
the Hb ≥ 12 g/dL and Hb < 10 g/dL groups (P = 0.459; 
Fig. 2A). Within the 40 ≤ age < 60 years and age ≥ 60 years 
groups, the 10 ≤ Hb < 12 g/dL group had significantly su-
perior overall patient survival compared to the Hb < 10 g/
dL group (P = 0.006 for the 40 ≤ age < 60 years; P < 0.001 
for the age ≥ 60 years). There was a trend toward better 
overall patient survival in the Hb ≥ 12 g/dL group com-
pared to the Hb < 10 g/dL group, but the difference was 
not statistically significant (P = 0.919 for the 40 ≤ age < 60 
years group; P = 0.086 for the age ≥ 60 years group; Fig. 
2C, D). The Hb ≥ 12 g/dL group had inferior overall sur-
vival than the 10 ≤ Hb < 12 g/dL group (P = 0.034), where-
as survival of the Hb < 10 g/dL group was comparable to 
that in the 10 ≤ Hb < 12 g/dL group (P = 0.475; Fig. 2B).
In a Cox proportional hazards model, for both the 40 ≤ 
age < 60 years and age ≥ 60 years groups, a lower Hb con-
centration (Hb < 10 g/dL) was associated with significantly 
increased risk of all causes of death (adjusted HR, 1.719; 
95% CI, 1.158-2.252; P = 0.007 in the 40 ≤ age < 60 years 
group; and adjusted HR, 2.098; 95% CI, 1.567-2.808; P < 
0.001 in the age ≥ 60 years group; Fig. 3B, C), but no such 
association was found for the age < 40 years group (Fig. 
3A).
Cardiovascular disease (CVD)-related death 
A total of 105 cases of CVD-related death occurred 
during the follow-up period. Among the overall study 
population, the 10 ≤ Hb < 12 g/dL group had the lowest 
incidence of CVD-related death (P < 0.001). In the age 
< 40 years and 40 ≤ age < 60 years groups, the incidence 
of CVD-related death was not different among the three 
Hb concentration groups (Fig. 4B, C). In contrast, in the 
age ≥ 60 years group, the lower Hb group (Hb < 10 g/dL) 
had the greatest incidence of CVD-related death among 
the three groups (P < 0.001; Fig. 4D). In the multivariate 
analyses, after adjustment for sex, primary renal disease, 
and duration of dialysis, a lower Hb concentration (Hb < 
10 g/dL) was an independent risk factor for CVD-related 
death in the age ≥ 60 years group (adjusted HR, 2.796; 95% 
CI, 1.669-4.686; P < 0.001; Fig. 5C). The Hb concentration 
was not significant associated with the incidence of CVD-
related death in the age < 40 years and 40 ≤ age < 60 years 
groups (Fig. 5A, B).
Overall hospitalization and cardiovascular hospitalization 
A total of 2,188 (64.2%) patients were hospitalized dur-
ing the follow-up period. In the overall study population, 
the Hb < 10 g/dL group had a significantly greater inci-
dence of hospitalization (n = 605, 70.5%) than the 10 ≤ Hb < 
Hb < 10 g/dL
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Figure 3. Forest plot of hazard ratios (HR) for overall mortality. 
All-cause mortality stratified by hemoglobin (Hb) level for patients 
(A) under 40 years of age, (B) aged between 40 to 60 years, and (C) 
over 60 years of age. 
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12 (n = 1,392, 62.8%) and Hb ≥ 12 g/dL groups (n = 191, 
57.0%; P values for all < 0.05). Fig. 6 shows the hazard 
ratios (HR) of all-cause and CVD-related hospitalization 
according to patient age and mean Hb concentration, 
after adjustment for sex, primary renal disease, and dura-
tion of dialysis. In the age < 40 years group, there were no 
significant differences in overall hospitalization accord-
ing to the mean Hb concentration. However, among the 
40 ≤ age < 60 years and age ≥ 60 years groups, Hb < 10 g/
dL itself increased the risk of overall hospitalization as 
compared to 10 < Hb ≤ 12 (adjusted HR, 1.572; 95% CI, 
1.213-2.036; P = 0.001, for the 40 ≤ age < 60 years group; 
adjusted HR, 1.455; 95% CI, 1.037-2.043; P < 0.001, for 
the age ≥ 60 years group). Among the age < 40 years and 
40 ≤ age < 60 years groups, a target Hb ≥ 12 g/dL did 
not significantly influence CVD-related hospitalization; 
whereas, among elderly patients (age > 60 years), a target 
Hb ≥ 12 g/dL significantly reduced the risk of all-cause 
hospitalization (adjusted HR, 0.544; 95% CI, 0.362-0.820; 
P = 0.004) and CVD-related hospitalization (adjusted HR, 
0.463; 95% CI, 0.242-0.887; P = 0.020).
Discussion 
In this study, we found that overcorrected Hb concen-
trations or anemia in dialysis patients had differential im-
pacts on the clinical outcomes according to the patient’s 
age. The impact of anemia was more significant in elderly 
ESRD patients than in the young patients. In contrast, 
overcorrected Hb concentrations had more significant 
impact in the younger ESRD patients. Therefore, our re-
sults suggest that a differential approach based on the 
patient’s age is required for the management of anemia 
in dialysis patients. 




















































































































Figure 4. Comparison of cardiovascular disease (CVD)-related death according to patient age. (A) CVD-related death according to he-
moglobin (Hb) concentration in the overall population, (B) in patients under 40 years of age, (C) aged between 40 to 60 years, and (D) over 
60 years of age. 
*P < 0.05 vs. Hb < 10.
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We first compared the baseline characteristics ac-
cording to the ages of the participants. We divided the 
patients into three age groups, age < 40, 40 ≤ age < 60, 
and age ≥ 60. The results of the baseline laboratory study 
indicated in all three age groups, most patients fell into 
the 10 ≤ Hb < 12 g/dL group (56% to 69%), followed by the 
Hb < 10 g/dL and Hb ≥ 12 g/dL groups respectively. Com-
pared to the other age groups, the overcorrection rate was 
slightly greater in the age < 40 years group with Hb ≥ 12 
g/dL, which reflects the tendency to set higher Hb targets 
for younger patients. However, the serum albumin con-
centration, which reflects the nutritional status of dialysis 
patients, did not differ among the three age groups, nor 
did serum ferritin or TSAT concentrations. Other markers 
related to anemia, such as iPTH, and C- reactive protein 
concentrations, also did not differ according to the pa-
tient’s age. These findings suggest that the baseline con-
dition associated with anemia may not differ according 
to the patient’s age. 
Next, we investigated the impact of anemia on overall 
patient survival in each age group. As we expected, pa-
tient survival was greatest when the patient’s Hb concen-
tration ranged between 10 and 12 g/dL, in both the over-
all patient population and each age subgroup. However, 
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Figure 5. Forest plot of hazard ratios (HR) for cardiovascular 
disease (CVD)-related mortality. All-cause mortality stratified by 
hemoglobin (Hb) level for patients (A) under 40 years of age, (B) be-
tween 40 to 60 years of age, and (C) over 60 years of age. 
Figure 6. Forest plot of hazard ratios 
(HR) of (A) all-cause hospitalization 
and (B) cardiovascular disease (CVD)-
related hospitalization of patients 
under 40 years of age, (C) all-cause 
hospitalization and (D) CVD-related 
hospitalization of patients between 
40 and 60 years of age, (E) all-cause 
hospitalization and (F) CVD-related 
hospitalization of patients over 60 
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patient survival according to the patient’s age: anemia 
was associated with lower patient survival in elderly pa-
tients, but did not influence survival in the younger pa-
tient groups. When we compared the incidence of CVD-
related death between the young and elderly patients 
according to their Hb concentrations, the incidence of 
CVD-related mortality was greater when Hb < 10 g/dL, 
which indicated that undercorrection of anemia in elder-
ly patients is associated with greater risk of CVD-related 
deaths. These trends were also confirmed in a review of 
the multivariate analyses. 
This differential impact may be partially accounted for 
by the association between frailty and anemia in elderly 
patients [9,10]. In elderly populations, mild anemia is in-
dependently associated with an increased risk of frailty, 
and the poorer prognosis associated with lower Hb con-
centrations may be related to decreased physical activity 
[11,12]. The risk of CVD-related death may be attributed 
to the tissue hypoxia caused by anemia, which promotes 
left ventricular hypertrophy (LVH), thereby causing death 
in elderly patients [13]. Previous studies have reported 
that aging increases the incidence and severity of LVH 
in dialysis patients. Furthermore, Hb was found to be an 
age-dependent risk factor for LVH [14]. The effect may 
be more pronounced in elderly patients, who are vulner-
able to LVH [15]. Anemia promotes cardiac structural 
and functional abnormalities, and is a CVD-related death 
risk factor in ESRD, especially in elderly dialysis patients 
[16,17]. Thus, further considerations or investigations are 
required [18].
Indeed, many previous reports have suggested that the 
incidence of hospitalization in ESRD patients is associ-
ated with a significant decline in Hb [19], and aging and 
frailty synergistically increased the risk of all-cause and 
CVD-related hospitalization [20]. Interestingly, among el-
derly dialysis patients, higher Hb concentrations were as-
sociated with significantly reduced risk for all-cause and 
CVD-related hospitalization, a finding which was seen to 
be inconsistent with young dialysis patients. This result 
may suggest that maintaining Hb concentrations within 
a more physiologically normal range (≥ 12 g/dL) may be 
adequate for reducing the short-term risk of all-cause 
and cardiovascular morbidity in elderly HD patients; 
however, further investigation may be required to clarify 
this issue and its clinical applications. 
Some studies have reported that the effect of anemia on 
overall or cardiovascular mortality may be less significant 
in young ESRD patients as compared to elderly ESRD pa-
tients, since they have fewer comorbid conditions [21-
23]. In addition, the prevalence of CVD among young 
adults with ESRD is lower than in elderly ESRD patients, 
and the types of CVD are also considered different. For 
example, the most common cardiovascular diagnoses in 
young ESRD patients have been reported to include LVH, 
congestive heart failure, and arrhythmias, whereas coro-
nary artery disease is most commonly found in elderly 
ESRD patients [24]. Thus, young ESRD patients do not 
appear to share the specific cardiovascular risk factors 
that are commonly present in elderly ESRD patients, and 
which may contribute to cardiovascular deaths associ-
ated with higher Hb concentrations. Therefore, young 
ESRD patients with may be better able to tolerate elevat-
ed Hb concentrations than elderly ESRD patients. 
Accordingly, this present study must be understood 
in the context of the limitations of a large-scale registry 
analysis, and the possibility of unmeasured confounders. 
For example, the details of the patients’ type of cardiovas-
cular disease or of comorbidities were not available for 
analysis. Secondly, the follow-up duration of this registry 
was relatively short and the death and CVD-related death 
rarely occurred during this period. Third, this study de-
fined old age as being greater than 60 years of age; how-
ever, the cut-off value defining ‘old age’ or ‘elderly’ status 
may be controversial and may differ from this assess-
ment. Finally, the under 40 years of age group comprised 
a relatively small proportion of the overall study popu-
lation, hence, the incidence of overall or CVD-related 
death may have been underestimated in this age group. 
Taken together, anemia had a more significant impact 
on overall and CVD-related mortality and on the inci-
dence of hospitalization in elderly patients on dialysis in 
comparison with the relatively young ESRD patients in 
our study. In contrast, elderly ESRD patients with a Hb 
concentration ≥ 12 g/dL did not have an increased short-
term risk of all-cause mortality. Our results may suggest 
that more strict management of anemia in ESRD patients 
may be required in elderly ESRD patients, and also that 
there is a need for future prospective, randomized trials 
to identify an appropriate Hb target range to minimize 
the risk of CVD morbidity and mortality in elderly HD 
patients. 
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